首页> 外国专利> DIAGNOSTIC AND PROGNOSTIC TEST FOR STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS)

DIAGNOSTIC AND PROGNOSTIC TEST FOR STURGE-WEBER SYNDROME, KLIPPEL-TRENAUNAY-WEBER SYNDROME, AND PORT-WINE STAINS (PWSS)

机译:喘振综合征,克里普尔-特雷纳尼-韦伯综合征和葡萄酒斑(PWSS)的诊断和预后测试

摘要

The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing Sturge-Weber Syndrome (SWS), Klippel-Trenaunay-Weber Syndrome (KTWS), and Port Wine Stains (PWS). In one embodiment, a method for prognosing or monitoring treatment of a patient with SWS, KTWS and/or PWS comprises the steps of (a) providing a sample from the patient undergoing treatment; (b) determining the number of alleles in the sample comprising at least one activating somatic mutation in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene or protein; (c) comparing the number of alleles comprising the at least one somatic mutation to the number of alleles comprising the somatic mutation from a patient sample provided prior to undergoing treatment; and (d) determining that the patient is improving if there is a decrease in the number of alleles comprising the at least one somatic mutation from the sample of step (a).
机译:本发明涉及神经和皮肤疾病领域。更具体地说,本发明提供了用于诊断和预测斯特吉-韦伯综合症(SWS),克利佩尔-特雷纳奈-韦伯综合症(KTWS)和波特酒渍(PWS)的方法和组合物。在一个实施例中,一种用于用SWS,KTWS和/或PWS预后或监视患者治疗的方法包括以下步骤:(a)从接受治疗的患者中提供样品; (b)确定在鸟嘌呤核苷酸结合蛋白G亚基α(GNAQ)基因或蛋白中包含至少一个激活的体细胞突变的样品中的等位基因数目; (c)将包含至少一种体细胞突变的等位基因的数目与来自接受治疗前提供的患者样品的包含体细胞突变的等位基因的数目进行比较; (d)如果步骤(a)的样品中包含至少一种体细胞突变的等位基因数目减少,则确定患者正在改善。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号